The Contracting Authority – the Polish Lymphoma Research Group (PLRG) hereby informs that by 9 June 2026, two (2) offers were submitted in response to the procedure concerning the provision of services consisting in making available a platform for the central review of PET/CT scans and performing imaging study interpretations for the non-commercial clinical trial:
“Efficacy and Tolerability of N-AVD compared to BrECADD in Patients with Advanced Hodgkin Lymphoma (N-BRAVE)”, Protocol No. PLRG-HL05, EU CT No. 2026-525263-41-00, financed from the state budget under funding granted by the Medical Research Agency (Agencja Badań Medycznych).
Following the market analysis and evaluation of the submitted offers in accordance with the requirements set out in Request for Quotation No. 04/2026, the offer submitted by Pixilib SAS was considered the most advantageous.
The offer is not subject to rejection, as it meets all requirements specified by the Contracting Authority and achieved the highest score according to the evaluation criteria adopted in the procurement procedure.
Consequently, a contract will be concluded with the above-mentioned Contractor.
We encourage you to download:
- Information on the Opening and Selection of the Offer.
